Market Updates

2026 Cancer Care M&A Market Update: Oncology Consolidation Gains Momentum

Is Now the Right Time to Sell Your Oncology Practice?

Consolidation in the oncology market continues to accelerate, punctuated by the market’s most recent headline transaction. In October 2026, Cencora announced it would acquire a majority stake in American Oncology Network (AON) in a deal valued at roughly $2.4 billion. AON is a physician-led community oncology network with about 350 providers across 21 states. Cencora, one of the nation’s largest drug distributors, already owns a majority stake in OneOncology, another leading community oncology platform.

The deal is a clear indicator of things to come. Drug distributors, private equity sponsors, and large health systems are all competing for high-quality, physician-owned cancer care practices and not afraid to place large price tags on deserving targets. Each wants to build scale in a specialty with strong, recurring revenue, driven by rising cancer incidence and continuing advances in treatment. Buyers are chasing a limited supply of quality, profitable practices, and that competition is producing premium valuations for the practices that fit.

Through PGP’s extensive experience across the multiple verticals of Cancer Care, we have been able to track the primary drivers of the market. Informed through longstanding industry relationships and live client engagements, this white paper is informed by PGPs deep industry expertise.

Why Does the Oncology Market in 2026-2027 Matter Now?

The U.S. oncology market is one of the largest and most resilient subsectors in healthcare. Global cancer medicine spending reached $252 billion in 2024 and is projected to reach $441 billion by 2029, reflecting average annual growth of 11.8%. The United States accounted for approximately 46% of global oncology spending in 2024, with U.S. spending expected to approach $180 billion by 2028. 1 2

The American Cancer Society projected more than 2 million new cancer cases in the United States in 2024, which was the first time that threshold has been crossed. 3  Lung, breast, prostate, and colorectal cancers account for the largest share of cases and drive the bulk of treatment revenue.

Through long standing relationships with key physician leadership at both private practices and industry consolidators, GP continues to monitor the ongoing shift in cancer care delivery; moving away from hospital settings toward independent practices. A Health Affairs study found that insurers paid approximately double for the same infused cancer drugs in hospital outpatient departments compared to independent physician offices. 4 Payors are increasingly directing patients toward lower-cost community settings, creating a substantial opportunity for well-positioned independent practices.

Consolidators such as McKesson, Cencora, and Cardinal Health, which collectively control over 90% of the U.S. pharmaceutical wholesale market, have reiterated to PGP through our regular touchpoints as well as live client mandates; their appetite to partner with more quality practices.5 Key executives at these distributors have describe to PGP their heightened intested in expanding further into the provider sector. Highlighted by multiple transactions involved competitors, namely The U.S. Oncology Network (McKesson), Integrated Oncology Network (Cardinal Health), OneOncology and most recently American Oncology Network (Cencora),. Their strategy is driven by the desire to secure downstream drug purchasing volume, and they are often willing to pay meaningful premiums to own the physician networks that direct it. This dynamic is a key component of the value creation thesis for these buyers.

What Is My Oncology Practice Worth? Understanding Valuation Multiples

Informed through PGPs most recently transaction processes in the Cancer Care space, oncology practice valuations vary based on factors such as size, revenue mix, geographic location, and buyer type. Understanding where your practice fits in the market and which buyers may value it most is key to maximizing your outcome.

Smaller practices with less than $3 million of EBITDA typically transact in the mid- to high-single-digit EBITDA Multiple range, while larger practices generating between $5 million and $10 million of EBITDA often command a double-digit EBITDA multiple due to greater scale, stronger drug purchasing volume, and value-based care capabilities. Highly scaled oncology platforms can achieve premium valuations above 12.0x EBITDA, driven by network scale, purchasing leverage, ancillary service offerings, and clinical trial infrastructure. Understanding how buyers evaluate scale, drug purchasing volume and value-based care capabilities is critical to positioning a practice for a successful transaction and maximizing value.

Cencora’s acquisition of full control of OneOncology in 2025 (in 2023 Cencora purchased a 35% stake with an option to buy the remainder) at a valuation of approximately 19x EBITDA, an EV of $7.4b and cash consideration of $5b, is representative of the appetite for scaled oncology assets.6 Cardinal Health’s acquisitions of Specialty Networks and ION were completed at a combined $2.3 billion, anchoring its Navista community oncology network.7 8 McKesson’s $2.5 billion acquisition of a 70% MSO stake in Florida Cancer Specialists expanded the US Oncology Network to more than 700 locations.9 Most recently, in October 2026, Cencora acquired American Oncology Network for $2.4b, adding 350 oncology providers across 21 states. 10 The dramatic influx of capital into the provision of oncology is indicative of the sheer interest in the specialty right now.

How Do I Achieve A Premium Value For My Oncology Practice?

Informed by both ongoing dialogue with buyers as well as supported by outcomes in PGP’s transaction processes for our clients in the space, PGP has developed the following list of key variables that drive value in a transaction process:

•Scale and Market Position: Multiple sites and a strong referral base in a defined geography, with a durable share of local cancer care.
•Drug Economics: Meaningful, well-documented drug purchasing volume and a clean 340B, GPO, and rebate profile.
•Physician Bench: A stable, diversified physician group with a credible succession plan, not dependence on a few founders.
•Ancillary Services: In-house or integrated radiation oncology, imaging, lab, pharmacy, and genomic testing that capture revenue and improve continuity of care.
•Clinical Research: An active trial portfolio, which buyers increasingly view as a differentiator and a source of pharma partnerships.
•Value-Based Performance: Participation and results in the Enhancing Oncology Model or commercial value-based arrangements, supported by quality and total-cost-of-care data.
•Earnings Quality: Clean financials, sustainable margins that do not depend on one-time drug pricing windfalls, and strong coding, compliance, and revenue-cycle processes.

How Do Buyers Create Value and Repair Income For My Oncology Practice?

Transactions are more than just a buyout or check at closing. National MSOs and Distributors bring value creation that can change a practice’s ability to recruit and stay competitive in their market for the foreseeable future. While each strategic partner brings a different menu of value creation levers, PGP has been able to congregate the most common initiatives buyers look to develop with newly partnered practices. These variables have been communicated to PGP by the primary buyers in the industry and supported through on-going discussions PGP has with practices that have consummated partnerships in the space:

•Managed care contracting: Leverage aggregated network patient volume and geographic density to negotiate superior commercial fee schedules and unlock bonus pools in value-based care arrangements.
•Drug spend savings: Scale unlocks top drug purchasing tiering and direct vertical integration in the case of drug distributor backed platforms such as Cardinal Health, Cencora, and McKesson.
•Medical supplies purchasing: Centralized enterprise purchasing agreements eliminate fragmented regional distributor markups on medical supplies, lowering cost across the network, if supplies are not vertically integrated.
•Provider recruitment and onboarding: Dedicated corporate recruitment engine eliminates expensive locum coverage and third-party placement fees, while centralized onboarding shortens the ramp-up for newly added oncologists.
•RCM costs: Migrating billing to a centralized, specialized oncology RCM infrastructure reduces billing costs as a percentage of collections and revenue leakage caused by prior authorization denials and missed co-pay assistance on drug regimens.
•Other vendor cost savings: Consolidating finance, HR, cyber and malpractice insurance policies, telecommunications, 401k, and group health benefit plans under master corporate contracts meaningfully reduces per-partner administrative overhead.

What Is Driving the Oncology Market in 2026?

Strong industry tailwinds are driving significant demand for oncology practices, while rising drug costs, reimbursement pressure, administrative burden, and operational complexity are increasing pressure on independent owners. As a result, scale and institutional support have become more valuable, and many practice owners are exploring sales or partnerships at a time when buyer interest and valuations remain strong.

The following key dynamics have been identified by PGP through conversations with the buyer community throughout our transaction processes as industry tailwinds that make independent oncology practices highly attractive acquisition targets to drug distributors and strategic acquirers:

•Growing cancer incidence and treatment volume. Millions of new cases are diagnosed in the U.S. each year, providing a durable, recurring patient base that continues to expand with an aging population.
•Therapeutic innovation driving revenue. Cancer treatment has evolved rapidly, with new medicines reaching patients at a significantly faster rate than in the prior decade.
•Shift by payors toward independent practice models. Payors are actively directing patients toward independent practices
•Distributor arms race for physician networks. McKesson, Cencora, and Cardinal Health are aggressively expanding into the provider sector to capture and integrate downstream drug purchasing volume
•Shift Towards Value-Based Care. Medicare’s Enhancing Oncology Model continues to shift to rewarding practices for reducing the total cost of cancer care

Who Is Buying Oncology Practices Right Now?

The Oncology buyer universe is competitive and exceptionally well-capitalized. For physician-owners, the depth of buyer demand for oncology practices is directly value-accretive. In each of PGP’s client engagements in the Cancer Care sector, we engage buyers from several key buckets. These buyer buckets are informed and driven through constant market monitoring and industry conversations to ensure all potential parties are identified:

•Drug Distributor-Backed Networks – McKesson (US Oncology Network), Cencora (OneOncology), and Cardinal Health (Navista) are aggressively seeking to vertically integrate into the physician services sector
•Health Systems and Academic Medical Centers – Regional systems and major cancer centers remain active for practices in key geographies
•Single-Specialty PE-Backed MSO Platforms – Private equity-backed management service organizations focused on oncology, urology and multispecialty physician groups are actively seeking to acquire practices and affiliated ancillary services
•Private Equity Groups– Private equity sponsors continue to see significant opportunity in oncology platforms

Platform Name Sponsor Description
Integrated Oncology Network / Navista Cardinal Health Community oncology MSO and practice alliance; Cardinal acquired ION in 2024 for $1.1B, adding 100+ providers across 50+ locations in 10 states, offering radiation oncology, urology, and in-office ancillaries.
OneOncology Cencora National community oncology platform; Cencora bought out TPG’s stake in 2025 ($7.4b valuation) and acquired American Oncology Network in Oct-26, adding 350 providers in 21 states.
The US Oncology Network McKesson Largest U.S. community oncology network, with 2,500+ providers; expanded in 2024 through the $2.5b acquisition of Florida Cancer Specialists / Core Ventures.
Cancer Care Specialists Levitate Ridge Capital Southwest based community oncology platform acquired by Levitate Ridge in 2024; active regional expansion in the west with multiple transactions in the pipeline.
Which Oncology Transactions Have the Most Active Acquirers Completed Recently? | PGP

Which Oncology Transactions Have the Most Active Acquirers Completed Recently?

PGP brings extensive experience advising businesses across the cancer care sector. Leveraging its work with adjacent provider services such as urology, OB/GYN, and pharma services, PGP applies unmatched industry expertise to drive value and partnership in our oncology and radiation oncology engagements.

In addition to the direct work PGP is doing in the oncology space, our firm tracks all deal activity to provide updated and accurate market intelligence to our clients. This deal tracking allows our firm to be a thought leader on the major trends in oncology consolidation and to identify key changes taking place in the sector.

Through both publicly available data that our team tracks and proprietary conversations with industry leaders, PGP has been able to track the following key transactions involving the industry’s most active acquirers:

OneOncology (Cencora) Recent Transactions

DateTargetGeography
Apr 2025Beacon ClinicNorthwest
Apr 2025New York Oncology HematologyNortheast
Jun 2025The START Center for Cancer CareSouth
Jun 2025Hematology and Oncology ClinicSoutheast
Oct 2025SunState Medical Specialists (Genesis Care USA of Florida)Southeast
Nov 2025Cancer Specialists of North FloridaSoutheast
Nov 2025Chesapeake Oncology-Hematology AssociatesMid-Atlantic
Dec 2025Ventura County Oncology HematologySouthwest
Dec 2025OneOncology (acquiring TPG’s equity interest)National
Oct 2026American Oncology Network (AEA Growth / Public)National

American Oncology Network (Acquired by Cencora Oct-26) Recent Transactions

DateTargetGeography
Aug 2025Conway Hematology OncologySouth
Mar 2026Oncology ConsultantsSouth
May 2026Eckhart OncologyMidwest

Navista (Cardinal Health) Recent Transactions

DateTargetGeography
Mar 2024Specialty NetworksNational
Dec 2024Integrated Oncology Network (Silver Oak)National

The U.S. Oncology Network (McKesson) Recent Transactions

DateTargetGeography
Jul 2024Florida Cancer Specialists / CORE VenturesSoutheast
Aug 2024Tennessee Cancer SpecialistsMidsouth
Sep 2024Illinois CancerCareMidwest
Aug 2026GW Cancer CenterMid-Atlantic

Cancer Care Specialists (Levitate Ridge Capital) Recent Transactions

DateTargetGeography
Apr 2025Cancer Care SpecialistsSouthwest
Apr 2026Cancer Center Oncology Medical GroupSouthwest

Why Is 2026-2027 a Peak Window for Oncology Practice Founders to Transact?

Market conditions seldom align this well across all dimensions at the same time.
●Strong buyer demand. Expansion by drug distributors, active private equity investment, and health systems seeking greater scale have created a favorable market for sellers.
●Increasing reimbursement pressure. Medicare cuts, potential 340B changes, and growing administrative burdens are making it more difficult to remain independent.
●Rising treatment complexity. New therapies and advanced diagnostics require significant capital investment that many independent practices cannot easily support on their own.
●Ongoing distributor competition. McKesson, Cencora, and Cardinal Health continue to compete aggressively for physician network partnerships, supporting strong valuations for sellers.
●Succession and liquidity planning. Many physician owners are pursuing transactions to reduce personal risk, gain operational support, and create greater financial flexibility while market valuations remain strong.

What Is PGP’s Perspective on the Oncology Market?

As the oncology landscape continues to evolve, independent practices are facing increasing pressure from rising drug costs, staffing shortages, reimbursement changes, and growing administrative complexity. At the same time, larger oncology platforms are benefiting from greater scale, stronger purchasing leverage, and broader operational infrastructure. Rising drug costs, reimbursement changes and the scale of larger oncology platforms are leading many physicians to evaluate strategic partnerships, affiliations, or practice sales to reduce financial and operational burden while continuing to deliver high-quality patient care.

The right potential buyer will depend on your practice’s specialty focus, geographic market, drug purchasing volume, and long-term goals for both the practice and your physicians. Some buyers prioritize preserving physician autonomy and culture, while others may offer greater operational support, access to capital, or the opportunity to participate in future equity growth.

Because every oncology practice is valued differently, it is important to position your practice thoughtfully and engage with the right group of buyers. A well-structured process can help maximize value, improve deal terms, and ensure alignment with your clinical, financial, and personal objectives.

Interested in learning more about market insights, valuation trends, and strategic opportunities?

Speak to a Senior Banker
No obligation. Completely confidential.
On This Page

Sources & Citations

3. Siegel et al. – Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians (American Cancer Society) 
4. Robinson, Whaley & Brown – Price Differences to Insurers for Infused Cancer Drugs in Hospital Outpatient Departments and Physician Offices. Health Affairs, 2021
5. Morningstar Equity Research – Investment Opportunities in Drug Distribution (May 2025) 
6. Scope Research - Cencora Purchases Remainder of OneOncology (~19x EBITDA)
7. Cardinal Health – Press Release, January 31, 2024. Cardinal Health to acquire Specialty Networks and its PPS Analytics platform.
8. Cardinal Health – Press Release, September 20, 2024. Cardinal Health to acquire Integrated Oncology Network.
9. McKesson Corporation – Press Release, August 26, 2024. McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures.
12, McKesson Corporation – Press Release, August 26, 2024. McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures.
Cencora - Press Release, October 21, 2026. Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology

Physician Growth Partners · This content is provided for informational purposes only and does not constitute legal, financial, or investment advice. All transaction data sourced as cited. © 2026 Physician Growth Advisors, LLC. All rights reserved.

Architectural blueprint for healthcare facility development.Blueprint design for healthcare project development.

Considering a healthcare transaction? Start with a confidential conversation.

Whether you are considering a recapitalization, merger, or full sale, or simply want to understand your options, PGP's senior bankers are ready to help.

"*" indicates required fields

Considering a healthcare transaction? Start with a confidential conversation.

Whether you are considering a recapitalization, merger, or full sale, or simply want to understand your options, PGP's senior bankers are ready to help.

"*" indicates required fields